Breast-feeding and risk of epithelial ovarian cancer.

School of Population Health, The University of Queensland, Herston, Australia.
Cancer Causes and Control (Impact Factor: 3.2). 04/2012; 23(6):919-27. DOI: 10.1007/s10552-012-9963-4
Source: PubMed

ABSTRACT Evidence suggests that breast-feeding may decrease the risk of epithelial ovarian cancer but it is not clear whether there is a relationship with duration of breast-feeding, patterns of breast-feeding, or particular histological subtypes of ovarian cancer. We sought to investigate these issues in detail.
Data from participants in a population-based study of ovarian cancer in western Washington State, USA (2002-2007) who had had at least one birth (881 cases and 1,345 controls) were used to assess relations between patterns of breast-feeding and ovarian cancer. Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI).
Women who ever breast-fed had a 22 % reduction in risk of ovarian cancer compared with those who never breast-fed (OR = 0.78, 95% CI 0.64-0.96) and risk reduction appeared greater with longer durations of feeding per child breast-fed (OR = 0.56, 95% CI 0.32-0.98 for 18 months average duration breast-feeding versus none). Introduction of supplementary feeds did not substantially alter these effects. The overall risk reduction appeared greatest for the endometrioid and clear cell subtypes (OR per month of average breast-feeding per child breast-fed = 0.944, 95% CI 0.903-0.987).
Among women who have had the opportunity to breast-feed, ever breast-feeding and increasing durations of episodes of breast-feeding for each breast-fed child are associated with a decrease in the risk of ovarian cancer independent of numbers of births, which may be strongest for the endometrioid subtype.

  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) have recently been identified as a novel class of gene regulators, playing an important role in various malignancies. In the present study, we investigated the role of miRNA-130b in the development of drug resistance in ovarian cancer cells. The human ovarian carcinoma cell line A2780 and paclitaxel-resistant A2780/Taxol cells were exposed to the chemotherapeutic agent cisplatin or paclitaxel in the presence or absence of transfected miR-130b. Cell viability assays were then performed using the Cell Counting Kit-8 (CCK-8) assay. Reverse transcription polymerase chain reaction and Western blotting were used to assess the messenger RNA (mRNA) and protein expression levels of glutathione S-transferase (GST)-π, multidrug resistance (MDR)1, or P-glycoprotein (P-gp). Following transfection, we found higher expression levels of miR-130b in A2780/Taxol cells than in A2780 cells (p < 0.05). Both A2780 and A2780/Taxol cells showed decreased sensitivity to paclitaxel and cisplatin compared with mock-transfected and negative control cancer cells (p < 0.05). The mRNA expression levels of MDR1 and GST-π (p < 0.05) and the protein expression levels of P-gp and GST-π were downregulated following miR-130b transfection in comparison to mock-transfected and negative control cancer cells. Our findings suggest that miRNA-130b may be involved in the development of drug resistance in ovarian cancer.
    Tumor Biology 08/2014; · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Across the state of Kansas, eighteen public health departments received funding through the 2011 Breastfeeding Grant Initiative to start a breastfeeding intervention. The main objective of this study was to evaluate the progress toward program goals and objectives. This study was a process evaluation. Qualitative data were collected from recipient health departments at two time-points during the program year. Structured, open-ended questions were asked through telephone interviews. This study examined: (1) progress toward program goals and objectives, (2) problems encountered during implementation, and (3) evaluation measures employed to assess program impact. All health departments reported making significant progress toward program goals and objectives and reported successful collaboration with other healthcare providers. The use of breast pumps, educational classes, and professional training of staff were reported as providing the best outcome in the promotion of breastfeeding. The majority of respondents did not measure program impact. From a public health perspective, it is important that infants receive breast milk for the first six months of life. It appears that goals and objectives set a priori guided health departments with the administration of their breastfeeding program. Results may be used to enhance and sustain delivery of breastfeeding support programs in Kansas communities.
    Evaluation and Program Planning 06/2014; 46C:87-93. · 0.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is still the deadliest of all gynecologic malignancies in women worldwide. This is attributed to two main features of these tumors, namely, (i) a diagnosis at an advanced tumor stage, and, (ii) the rapid onset of resistance to standard chemotherapy after an initial successful therapy with platin- and taxol-derivatives. Therefore, novel targets for an early diagnosis and better treatment options for these tumors are urgently needed. Epidemiological data show that induction and biology of ovarian cancer is related to life-time estrogen exposure. Also experimental data reveal that ovarian cancer cells share a number of estrogen regulated pathways with other hormone-dependent cancers, e.g., breast and endometrial cancer. However, ovarian cancer is a heterogeneous disease and the subtypes are quite different with respect to mutations, origins, behaviors, markers, and prognosis and respond differently to standard chemotherapy. Therefore, a characterization of ovarian cancer subtypes may lead to better treatment options for the various subtypes and in particular for the most frequently observed high-grade serous ovarian carcinoma. For this intention, further studies on estrogen-related pathways and estrogen formation in ovarian cancer cells are warranted. The review gives an overview on ovarian cancer subtypes and explains the role of estrogen in ovarian cancer. Furthermore, enzymes active to synthesize and metabolize estrogens are described and strategies to target these pathways are discussed.
    Frontiers in Endocrinology 11/2014; 5:192.


Available from